Maa Godawari Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.10 M
- Company Age 22 Year, 17 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -14.62%
- Profit Growth 107.87%
- Ebitda 55.33%
- Net Worth 3.48%
- Total Assets 2.17%
About Maa Godawari Biotech
Maa Godawari Biotech Private Limited (MGBPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 January 2003 and has a history of 22 years. Its registered office is in Raipur, Chattisgarh, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kamal Agrawal and Pramod Agrawal serve as directors at the Company.
Company Details
-
Location
Raipur, Chattisgarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01122CT2003PTC015515
-
Company No.
015515
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jan 2003
-
Date of AGM
05 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chhattisgarh
Industry
Who are the key members and board of directors at Maa Godawari Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Agrawal
|
Director | 17-Jan-2003 | Current |
|
Pramod Agrawal
|
Director | 17-Jan-2003 | Current |
Financial Performance of Maa Godawari Biotech.
Maa Godawari Biotech Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 14.62% decrease. The company also saw a substantial improvement in profitability, with a 107.87% increase in profit. The company's net worth moved up by a moderate rise of 3.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maa Godawari Biotech?
In 2018, Maa Godawari Biotech had a promoter holding of 80.95% and a public holding of 19.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Akash Ispat Private LimitedKamal Agrawal is a mutual person
-
Zee Steels Private Limited
Kamal Agrawal is a mutual person
-
Shiv-Ashish Investments Private Limited
Kamal Agrawal is a mutual person
-
Ramnath Bhimsen Eduresource Llp
Pramod Agrawal is a mutual person
-
Potential Vyapaar Pvt Ltd
Pramod Agrawal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maa Godawari Biotech?
Unlock and access historical data on people associated with Maa Godawari Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maa Godawari Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maa Godawari Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.